Champions Oncology, Inc. — Q1 FY2023 Form 10-Q
Reporting period: Three months ended July 31, 2022. Champions Oncology provides technology-enabled oncology research and drug-discovery services, including pharmacology studies and data/software offerings. Financial amounts below are in thousands of dollars except per-share data.
Financial results and position
| Metric | Q1 FY2023 | Q1 FY2022 |
|---|---|---|
| Oncology services revenue | $13,745 | $11,253 |
| Cost of oncology services | $7,052 | $5,396 |
| Gross margin | 48.7% | 52.0% |
| Research and development | $2,887 | $2,304 |
| Sales and marketing | $1,692 | $1,574 |
| General and administrative | $2,398 | $2,154 |
| Operating loss | $(284) | $(175) |
| Net loss | $(319) | $(172) |
| Basic and diluted loss per share | $(0.02) | $(0.01) |
| Cash used in operating activities | $(195) | Cash provided: $216 |
| Capital expenditures | $(754) | $(907) |
Revenue grew 22.1%, primarily from larger pharmacology studies across in-vivo and ex-vivo platforms. Pharmacology services generated $12,756 of revenue; other TOS revenue was $948 and personalized oncology services revenue was $41. Cost of services rose 30.7%, outpacing revenue growth, and gross margin declined 3.3 percentage points. The filing attributes the lower margin to study-related costs incurred ahead of revenue recognition and SaaS costs expensed in the current period rather than capitalized as in the prior-year period.
R&D expense increased 25.3%, mainly due to compensation and laboratory supplies for investment in the therapeutic drug-discovery platform. Sales and marketing rose 7.5%, and G&A rose 11.3%, with the latter increase mainly attributed to IT infrastructure costs.
At July 31, 2022, cash was $8,058, down from $9,007 at April 30, 2022; total current assets were $18,371 and current liabilities were $16,620, for working capital of approximately $1,751. Accounts receivable, net, was $9,355 and deferred revenue was $10,885. Total assets were $34,390 and stockholders’ equity was $8,983. The filing reports no off-balance-sheet debt or similar obligations. Lease liabilities totaled $9,226, including $1,099 current and $8,127 non-current; these are operating lease obligations, not reported borrowings. The company also recognized finance leases for laboratory equipment tied to supply-purchase commitments.
Liquidity, outlook, risks and other matters
Management believes cash on hand and expected positive operating cash flow for fiscal 2023 will fund operations for at least 12 months from the filing date. If revenue expectations are not met, management says it could implement cost reductions without disrupting the business or restructuring the company. The company may need additional capital if circumstances require it, but there is no assurance financing would be available on acceptable terms. No quantified revenue or earnings guidance is provided.
The company reported an accumulated deficit of approximately $72.3 million and a quarterly net loss of $319. Key risks include failure to achieve expected revenue and operating cash flow, funding needs, and execution of its research and product-development strategy. Management also identifies risks and uncertainties described in its annual report; the filing does not reproduce the full risk-factor discussion. It reports no current legal proceedings known to the company and no material internal-control changes; disclosure controls were deemed effective as of July 31, 2022. A $181 uncertain-tax-position liability remained recorded, and management did not expect unrecognized tax benefits to be recorded in the next 12 months. No registration-rights penalties were accrued, as the company stated it had filed the required registration statement and expected continued compliance.
Most important facts for investors to verify
- Whether revenue growth converts into improved gross margin, given service costs grew faster than revenue and margin fell to 48.7%.
- Whether management’s expected positive fiscal 2023 operating cash flow is achieved; quarterly operating cash flow was negative $195 and cash declined by $949.
- How R&D investment and SaaS/platform spending affect operating losses, cash needs, and the timing of revenue recognition.
- Cash runway and funding flexibility, including working capital, lease commitments, and the possibility that additional capital may be needed.
- Progress and commercial prospects for Lumin and the drug-discovery pipeline; the filing provides no quantified forward revenue or earnings guidance.